Published: June 3, 2024
Recent studies have shown that the endogenous cannabinoid system (ECS) of brain is essentially involved in pathogenesis Parkinson's disease (PD), influencing its symptoms by regulating level cannabinoids and altering activation receptors (CBR). Therefore, modulation ECS with new drugs developed for this purpose may prove to be a promising strategy treatment PD. However, fine regulation quite challenge due functional diversity CBR basal ganglia. Our review analyses effects modulators on experimental PD models patients PD, as well presents outlooks development motor non-motor
Language: Английский